Belizatinib is an investigational small molecule inhibitor primarily targeting the c-Met and ALK (anaplastic lymphoma kinase) pathways, which are implicated in the development and progression of certain cancers. It has shown potential in the treatment of non-small cell lung cancer (NSCLC), particularly in patients whose tumors exhibit ALK or c-Met abnormalities, such as gene rearrangements or amplifications. By inhibiting these kinases, belizatinib helps block signaling pathways that drive tumor cell growth, survival, and metastasis. It is being studied in clinical trials for its efficacy in patients who may have developed resistance to earlier-generation ALK inhibitors, offering a possible therapeutic option in refractory cases. Its dual inhibition profile may provide broader coverage in tumors with complex molecular drivers. Research is ongoing to determine optimal dosing, safety, and long-term outcomes in various cancer types beyond lung cancer, including other solid tumors with relevant genetic alterations.